BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25608839)

  • 1. SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers.
    Roisman A; Stanganelli C; Nagore VP; Richardson GV; Scassa ME; Bezares RF; Cabrejo M; Slavutsky I
    Tumour Biol; 2015 Jun; 36(6):4433-40. PubMed ID: 25608839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
    Stanganelli C; Travella A; Bezares R; Slavutsky I
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia in a young population.
    Alshemmari SH; Hamdah A; Pandita R; Kunhikrishnan A
    Leuk Res; 2021 Nov; 110():106668. PubMed ID: 34492597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
    Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity.
    Mansouri M; Sevov M; Fahlgren E; Tobin G; Jondal M; Osorio L; Roos G; Olivecrona G; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):301-6. PubMed ID: 19709746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
    Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.
    Visentin A; Facco M; Frezzato F; Castelli M; Trimarco V; Martini V; Gattazzo C; Severin F; Chiodin G; Martines A; Bonaldi L; Gianesello I; Pagnin E; Boscaro E; Piazza F; Zambello R; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):612-20.e1-5. PubMed ID: 26233718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
    Trojani A; Montillo M; Nichelatti M; Tedeschi A; Colombo C; Veronese S; Mura MA; Ricci F; Scarpati B; Colosimo A; Lodola M; Morra E
    Cancer Biomark; 2010; 6(1):1-9. PubMed ID: 20164537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.
    Cao X; Fan L; Fang C; Zhu DX; Dong HJ; Wang DM; Wang YH; Xu W; Li JY
    Med Oncol; 2012 Jun; 29(2):1190-6. PubMed ID: 21479697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.
    Negrini M; Cutrona G; Bassi C; Fabris S; Zagatti B; Colombo M; Ferracin M; D'Abundo L; Saccenti E; Matis S; Lionetti M; Agnelli L; Gentile M; Recchia AG; Bossio S; Reverberi D; Rigolin G; Calin GA; Sabbioni S; Russo G; Tassone P; Morabito F; Ferrarini M; Neri A
    Clin Cancer Res; 2014 Aug; 20(15):4141-53. PubMed ID: 24916701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.